Mesoblast Reports Fiscal Year Financial Results and Revenue Miss
Mesoblast Limited (MESO) has released its fiscal year financial results, reporting a revenue of $115 million. This figure represents a significant miss against market expectations, falling short by approximately $44 million. The company reported a gross profit on total sales when excluding amortization expenses of $115 million. Despite the revenue shortfall, the company continues to focus on its product pipeline, including Ryoncil and Rexlemestrocel-L, as it navigates regulatory milestones and clinical developments.

Tickers: $MESO